Signaturefd LLC Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Signaturefd LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,492 shares of the medical research company’s stock after purchasing an additional 287 shares during the quarter. Signaturefd LLC’s holdings in IQVIA were worth $577,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Laurel Wealth Advisors LLC grew its holdings in IQVIA by 1.1% in the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock valued at $927,000 after buying an additional 50 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after buying an additional 53 shares in the last quarter. Private Advisor Group LLC grew its holdings in IQVIA by 1.2% in the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock valued at $948,000 after buying an additional 56 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its stake in shares of IQVIA by 1.6% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after purchasing an additional 56 shares during the last quarter. Finally, Greenleaf Trust lifted its stake in shares of IQVIA by 1.9% in the 4th quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock valued at $730,000 after purchasing an additional 58 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 in the last quarter. 1.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Truist Financial upped their price target on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Robert W. Baird upped their price target on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. UBS Group upped their price target on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Barclays upped their price target on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $256.80.

IQVIA Trading Up 0.9 %

IQV opened at $240.84 on Thursday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a market cap of $43.71 billion, a P/E ratio of 33.04, a PEG ratio of 2.31 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The business’s 50-day simple moving average is $245.50 and its 200-day simple moving average is $222.69.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.54 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.